Design, Codon Optimization, and Bioinformatic-Assisted Development of a Chimeric Circumsporozoite Protein for Malaria Vaccine Production Using Duckweed (Lemna minor) as a Plant Bioreactor: Bioinformatic analysis of malaria surface antigen for vaccine developm
Trends in Peptide and Protein Sciences · 26.04.2025
DOI: 10.22037/tpps.v10i1.47613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Peptide and Protein Sciences, erschienen am 26.04.2025. Verfasst von Nima Rad und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Malaria remains a serious global health problem, causing high morbidity and mortality, especially in tropical and subtropical regions. The development of effective and scalable vaccines is crucial for the control of this disease. This study investigates the application of Lemna minor (duckweed) as a novel, cost-effective, and sustainable bioreactor for the production of a chimeric circumsporozoite protein (CSP), a key antigen for malaria vaccine development. The synthetic CSP (CS712) was designed using duckweed-specific codon tables and codon-optimized to increase expression efficiency. Comprehensive bioinformatic analyses were performed to evaluate its physicochemical properties, antigenicity, allergenicity, and immunogenic potential. The optimized CS712 protein exhibited favorable properties, including high structural stability validated by Ramachandran plot and ProSA-Web, a PI of 5.31, and strong antigenicity (78.67%) without any allergenicity. Epitope predictions showed robust B and T cell responses, while molecular docking studies confirmed effective interaction with Toll-like receptor 2 (TLR2), highlighting its ability to activate innate and adaptive immunity. The results underline the potential of duckweed as a versatile plant platform for the production of recombinant vaccines. The CS712 protein proves to be a promising candidate for the development of a malaria vaccine and offers an innovative approach combining bioinformatic-based design and plant biotechnology. This study not only advances malaria vaccination strategies but also highlights the broader applicability of plant-based systems to address global health challenges through sustainable and scalable solutions. HIGHLIGHTS Duckweed was utilized as a platform for recombinant protein production. A new chimeric circumsporozoite protein (CS712) from Malaria was optimized for expression in Lemna minor. The designed CS712 showed strong antigenicity and no allergenicity in bioinformatic analyses. Predicted epitopes highlighted robust B- and T-cell immune response potential. CS712 effectively interacted with TLR2, and could activate innate and adaptive immunity. You can listen to the audio abstract here.
Schlagwörter
Zitieren
APA
Rad, N., Arezoumandi, M., Taghipour, E., Frootan, F., & Salmanian, A. H. (2025). Design, Codon Optimization, and Bioinformatic-Assisted Development of a Chimeric Circumsporozoite Protein for Malaria Vaccine Production Using Duckweed (Lemna minor) as a Plant Bioreactor: Bioinformatic analysis of malaria surface antigen for vaccine developm. Trends in Peptide and Protein Sciences. https://doi.org/10.22037/tpps.v10i1.47613
Vancouver
Rad N, Arezoumandi M, Taghipour E, Frootan F, Salmanian AH. Design, Codon Optimization, and Bioinformatic-Assisted Development of a Chimeric Circumsporozoite Protein for Malaria Vaccine Production Using Duckweed (Lemna minor) as a Plant Bioreactor: Bioinformatic analysis of malaria surface antigen for vaccine developm. Trends in Peptide and Protein Sciences. 2025. doi:10.22037/tpps.v10i1.47613
BibTeX
@article{Rad2025,
author = {Rad, Nima and Arezoumandi, Mahdi and Taghipour, Elham and Frootan, Fateme and Salmanian, Ali Hatef},
title = {Design, Codon Optimization, and Bioinformatic-Assisted Development of a Chimeric Circumsporozoite Protein for Malaria Vaccine Production Using Duckweed (Lemna minor) as a Plant Bioreactor: Bioinformatic analysis of malaria surface antigen for vaccine developm},
journal = {Trends in Peptide and Protein Sciences},
year = {2025},
doi = {10.22037/tpps.v10i1.47613}
}
EUVIMED